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Aim To determine whether apoptosis is more common in 
previously punctured native veins than in non-punctured 
native veins among patients who undergo surgical cre-
ation of arteriovenous fistula (AVF) for dialysis access.
Methods Cephalic vein specimens were obtained from 
January 1, 2013 to December 31, 2014 from 60 patients, 30 
with previously punctured native veins and 30 with non-
punctured native veins. Before AVF placement, a 1-cm vein 
segment was excised from distal part of the vein for histo-
logical, histochemical, and immunohistochemical analysis. 
Vein specimens were divided into two portions along the 
longitudinal axis and stained with hematoxylin and eosin 
for routine histological evaluation. Immunohistochemical 
analysis was used to localize Bax, p53, caspase 3, and Bcl-2 
expression.
Results The group with previously punctured veins 
showed significantly increased caspase 3 (P < 0.001, two-
sided Fisher`s Exact Test) and Bax expression (P = 0.002, 
two-sided Fisher`s Exact Test) and significantly decreased 
Bcl-2 expression (P < 0.001, two-sided Fisher`s Exact Test) 
compared with the control group. There were no signifi-
cant differences between the groups in p53 expression 
(χ2 = 0.071, df = 1, P = 0.791). Fistula failure was significantly 
more common in the study group (26.7% vs 6.7%, χ2 = 4.32, 
df = 1, P = 0.038).
Conclusion Our study indicates a possible role of veni-
puncture in apoptosis development and a possible role of 
apoptosis in fistula failure, but we do not have sufficient 
evidence to conclude that it represents its main cause.
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The past two decades have seen a significant increase in 
the number of patients with end-stage renal disease re-
quiring hemodialysis and in the mortality rates of hemo-
dialysis patients. A common problem in hemodialysis pa-
tients is arteriovenous fistula (AVF) failure, a major cause of 
morbidity and hospitalization (1,2). Early native AVF failure 
(juxta-anastomotic stenosis) has a complex pathogenesis, 
and predisposing factors include a small artery (<1.5 to 2 
mm) and a small vein (<2.0 to 2.5 mm), surgical manipu-
lation and less-than-ideal technique, previous punctures, 
development of accessory veins that re-direct blood flow 
away from the primary venous drainage channel, hemody-
namic stressors, and a genetic predisposition to vasocon-
striction and neointimal hyperplasia after endothelial and 
smooth muscle injury (3-7).
Abnormalities in the apoptotic cell death control contrib-
ute to a variety of cardiovascular diseases such as athero-
sclerosis, aneurysm formation, ischemic cardiomyopathies, 
infarction, and varicose veins (8-10). Several studies have 
dealt with apoptosis in the varicose veins of the lower ex-
tremities (11,12), but there has been no research on the 
upper extremities veins. The only way to achieve this was 
to study the veins used for hemodialysis access. Apoptosis 
has a complex pathway, and various mediators regulating 
apoptosis and cell proliferation have been evaluated so far. 
It was found that cells with a mutated p53 gene cannot 
control genomic integrity and tend to escape from apop-
tosis (9). Bcl-2 family proteins, including pro- and antiapop-
totic members, participate in the p53 apoptotic pathway, 
and the equilibrium between these positive and negative 
regulatory proteins is essential for creating susceptibility to 
apoptosis (11,12).
The aim of the study was to evaluate apoptosis presence 
and extent in previously punctured and non-punctured 
native veins used to create AVF in hemodialysis patients. 
We also aimed to assess the number of patients with AVF 
failure and assess its association with apoptosis.
MaTerIaLS and MeThodS
Patients
Cephalic vein specimens were obtained from 60 patients 
with chronic renal disease (CRD) at the University Clini-
cal Center of Kosovo from January 1, 2013 to December 
31, 2014. The number of patients was determined on the 
basis of a similar study (13). The study group included pa-
tients with a previously punctured vein used to create AVF 
(n = 30) and the control group included patients with no 
previously punctured vein (n = 30). The indication for AVF 
creation was established according to the international 
recommendations (14-16).
All included patients had a competent deep venous sys-
tem without a history of thrombotic episodes and systol-
ic blood pressure higher than 100 mm Hg. The study did 
not include patients in whom AVF was not developed to 
sustain dialysis or who were thrombosed before the first 
successful cannulation, patients in whom AVF was cre-
ated with graft prosthesis, and patients with stenosis and 
thrombosis of the draining or central veins.
For each patient we collected data on age, sex, time of AVF 
creation, duration of CRD and dialysis, anatomic position 
of AVF, type of AVF, Doppler sonographic data before the 
creation of AVF, presence of comorbid conditions (diabe-
tes mellitus, coagulation disorder, malignancy, coronary 
artery disease, cerebrovascular disease, peripheral vascu-
lar disease, use of angiotensin-converting-enzyme inhibi-
tor inhibitors, statins, calcium antagonist, coumarin, plate-
let aggregation inhibitor, prior central catheter placement, 
hepatitis B surface antigen, hepatitis C virus, human im-
munodeficiency virus, history of intravenous drug abuse, 
smoking). The history of venipuncture was obtained from 
the patient or patient’s family member. Preoperative sono-
graphic mapping (Siemens Acuson X300 system [Erlan-
gen, Germany]; 7 to 15 MHz transducer) was performed by 
a vascular surgeon.
Preoperative evaluation
The veins were sequentially evaluated along the arm for 
diameter, patency, and depth. The exclusion criteria were 
stenosis and thrombosis of the draining or central veins. 
The appropriateness of the arteries and veins to create 
the AVF was based on the level of arterial atherosclerosis, 
blood flow, and the presence of thrombosis, and was as-
sessed as excellent, good, or sufficient (Table 1).
Surgical technique
Surgical procedure was performed on an outpatient basis 
(local anesthesia). The AVFs were created at the non-dom-
inant extremity. The patient was supine with the exam-
ined arm comfortably extended approximately 60° from 
the chest. AVFs were created in the usual manner (radial 
artery-cephalic vein, brachial artery-cephalic vein, ter-
mino-lateral anastomosis [end-to-side] using 6/0 or 
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7/0 polypropylene suture). The cephalic vein was excised. 
Intraoperatively, before creating AVF, a 1-cm long vein seg-
ment was excised from its distal part for histological and 
immunohistochemical analysis.
Specimens
The vessel samples were irrigated and dilated with hep-
arin-saline solution. AVF maturation was sonographically 
observed during 4-6 weeks depending on the patient’s 
general condition. AVF was considered to be sufficiently 
matured when blood flow reached 500 mL/min and ves-
sels’ diameter was 4 mm (3,14,17,18). Fistula failure was de-
fined as late failure, ie, an inability to use the matured AVF 
after at least 3 months of normal usage. Length of follow 
up to failure was one year after the first fistula puncture. 
Patients were followed up on 3, 6, 9, and 12 months, and 
AVF failure was noted. Hemodialysis was performed using 
the standard procedure; each procedure lasted 4 hours, 3 
times weekly using biocompatible polysulphone hemodi-
alysis membranes (Fresenius, Grove City, OH, USA) (15).
Tissue preparation
The collected specimens were fixed in 10% buffered solu-
tion containing 4% formaldehyde for 24 hours and embed-
ded in paraffin for conventional histology, histochemistry, 
and immunohistochemistry.
histology and histochemical staining
Specimens for histological evaluation were stained with 
hematoxylin and eosin (H&E). Results were obtained by 
two independent investigators who were blinded to the 
patient’s clinical findings. Mallory, Gomori, and Van Gieson’s 
elastotic staining were used to evaluate morphological 
changes in the veins.
Immunohistochemistry
For immunohistochemical analysis of apoptosis we select-
ed the most commonly used antibody panel: p53 mouse 
monoclonal antibody in a 1:50 dilution; Bcl-2 mouse mono-
clonal antibody in a 1:50 dilution; caspase 3 mouse mono-
clonal antibody in a 1:50 dilution; and Bax rabbit polyclonal 
antibody in a 1:500 dilution (all from DAKO, Glostrup, Den-
mark) (13,18).
Streptavidin-biotin-peroxidase method was performed ac-
cording to the manufacturer’s instructions (DAKO). Biotin-
conjugated secondary antibody was applied in a 1:200 
dilution for 1 hour at room temperature, followed by a 30-
minute incubation in Strept-AB complex for color devel-
opment and counterstaining with 3,3’-diaminobenzidine 
tetrahydrochloride and hematoxylin. The protein expres-
sion was evaluated using a semiquantitative assessment 
of positive cells by Filis et al (13). Scoring was as follows: 
no staining, minimum staining (1%-3%), moderate stain-
ing (>3%-50%), and maximum staining (>50%-100%). Cells 
that stained positive (cytoplasmic and nuclear staining) for 
the examined antibodies in the intima, media, and adven-
titia were counted at 400 × magnification and quantified in 
10 random fields per section. We used the tonsil as positive 
control for Bcl-2, caspase 3, and Bax, and breast tissue for 
p53. Negative control was obtained by omitting primary 
antibody.
Ethical approval was received from the University Clinical 
Center of Kosovo, Prishtina, University Hospital Center “Ses-
tre milosrdnice,” Zagreb, and University of Zagreb School 
TaBLe 1. The level of appropriateness of the arteries and veins to create the arteriovenous fistula
Internal diameter Wall Flow
arteries
excellent minimum of 2 mm no atheroma good
good minimum of 2 mm stiff artery wall with no atheroma average to good
sufficient minimum of 2 mm hard and fragile artery wall with atheroma average
Veins
excellent minimum of 2 mm without any clots and thrombosis, completely open proximal good flow, dilates and fills well with pres-
sure on the proximal part of the vein
good minimum of 2 mm without proximal obstruction, persisted proximal stenosis, 
which could be removable with dilatators
the vein is appropriately filled with blood 
after release of proximal pressure
sufficient minimum of 2 mm stiff wall, stenosis, or obstruction of the proximal part, dilata-
tors of maximum size of 2 Fresenius could pass through
low flow rate, proximal part without ap-
propriate blood and adequate dilatation
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of Medicine. Informed consent was obtained from all par-
ticipants.
Statistical analysis
Chi square test or Fisher Freeman Halton test were used to 
test the differences in the proportions of qualitative vari-
ables between the groups. Normality of quantitative vari-
able distributions was tested by Kolmogorov-Smirnov test. 
Mann-Whitney U was used to test the differences between 
quantitative variables that were not normally distributed. 
P < 0.05 was considered significant. For statistical analysis 
we used Dell Statistica, version 13 (Round Rock, TX, USA).
reSuLTS
According to preoperative physical examination and non-
invasive imaging findings, 60 patients on maintenance he-
modialysis with an AVF as vascular access were found to be 
appropriate candidates for this study (Table 2).
histology and histochemical staining
Routine H&E staining showed histological appearance of 
punctured and non-punctured vein specimens. Signs of 
apoptosis were visible in the form of pyknotic bodies. Mal-
lory and Gomori’s histochemical staining demonstrated 
a loss of elongated morphology of punctured veins and 
slightly increased collagen matrix, while Von Gieson’s elas-
tic staining showed degradation of elastic fibers compared 
with non-punctured veins (Figure 1).
expression of apoptotic and antiapoptotic markers (IhC)
In the study group, p53 showed no or minimal expression, 
Bcl-2 showed minimal and moderate expression, caspase 
FIgure 1. (A) Control vein, hematoxylin and eosin staining, ×100. hyphen indicates the intima (endothelium); one asterisk indicates 
the media; two asterisks indicate the adventitia. (B) Punctured vein, hematoxylin and eosin staining, ×200. hyphen indicates the inti-
ma (endothelium); one asterisk indicates the media; two asterisks indicate the adventitia. (C,D,E) Control vein. (C) Mallory trichrome 
staining; (D) gomori’s staining; (E) Van gieson’s staining. (F,G,H) Punctured vein. (F) Mallory trichrome staining; (G) gomori’s staining; 
(H) Van gieson’s staining.
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3 showed minimal, moderate, and maximal expression, 
while Bax showed no or minimal and moderate expres-
sion (Figure 2A-C and Table 3). In the control group, p53 
showed no or minimal expression, Bcl-2 showed minimal, 
moderate, and maximal expression, caspase 3 showed no 
or minimal expression, and Bax showed no or minimal ex-
pression (Figure 2D, E and Table 3).
The study group showed significantly increased caspase 
3 and Bax expression (P < 0.001, and P = 0.002, two-sid-
ed Fisher`s Exact Test, respectively) and significantly de-
creased Bcl-2 expression compared with the control group 
(P < 0.001, two-sided Fisher`s Exact Test). There were no 
significant differences between the groups in p53 expres-
sion (χ2 = 0.071, df = 1, P = 0.791) (Table 3). Fistula failure was 
significantly more common in the study group (26.7% vs 
6.7%, χ2 = 4.32, df = 1, P = 0.038) (Table 4).
dISCuSSIon
This study found increased caspase 3 and Bax expression 
and decreased Bcl-2 expression in the study group com-
pared with the control group and no significant differences 
in p53 expression between the groups. No similar studies 
have been published so far, but there are studies dealing 
with apoptosis in different vascular lesions, especially athero-
sclerosis and varicose veins. Specimens retrieved from pa-
tients with AVF restenosis more frequently contained apop-
tosis foci than specimens of primary atherosclerotic lesions 
(19). The adventitia of varicose vein specimens showed lack 
of immunopositivity for Bax, while atherosclerotic lesions of 
primary and restenotic types showed a lack of immunoposi-
TaBLe 2. Characteristics of patients with (study group) and 
without previously punctured native veins (control group)
Study 
group 
(n = 30)
Control 
group 
(n = 30) P
age (years), median/interquartile range 63.5/25 63/20.25 0.695†
Sex (male/female) 18/12 20/10 0.592*
no dialysis 11 (36.7) 10 (33.3) 0.787*
Central venous catheter
internal jugular vein  6 (20.0)  9 (30.0) 0.713*
femoral vein 11 (36.7)  8 (26.7)
subclavian vein  2 (6.7)  3 (10.0)
Serology
Hepatitis B surface antigen positive  2 (6.7)  2 (6.7) 1.000*
Hepatitis C virus positive  1 (3.3)  2 (6.7) 1.000*
Human immunodeficiency virus positive  0 (0)  0 (0)
Comorbidities
hypertension 26 (86.7) 21 (70.0) 0.117*
pulmonary disease  3 (10.0)  3 (10.0) 1.000*
hematologic disease 19 (63.3) 17 (56.7) 0.598*
diabetes 11 (36.7) 11 (36.7) 1.000*
peripheral vascular disease  2 (6.7)  2 (6.7) 1.000*
cerebrovascular disease  4 (13.3)  0 (0) 0.112*
rheumatologic disease  2 (6.7)  1 (3.3) 1.000*
cancer  2 (6.7)  5 (16.7) 0.424*
Choice of access site
non dominant extremity 24 (80.0) 28 (93.3) 0.254*
dominant extremity  6 (20.0)  2 (6.7)
Type of fistula
radial-cephalic fistula sin 15 (50.0) 15 (50.0) 0.892*
brachial-cephalic sin 10 (33.3) 12 (40.0)
radial-cephalic fistula dex  3 (10.0)  2 (6.7)
brachial-cephalic dex  2 (6.7)  1 (3.3)
*Fischer’s exact test.
†Mann-Whitney u test.
TaBLe 3. Comparison of apoptotic and antiapoptotic markers 
expression between patients with (study group) and without 
previously punctured native veins (control group)
Study group Control group P
p53
no staining 18 19 0.791*
minimum staining† 12 11
moderate staining 0 0
maximum staining 0 0
Bcl-2
no staining 0 0 <0.001*
minimum staining 20 3
moderate staining 10 20
maximum staining 0 7
Caspase 3
no staining 0 19 <0.001*
minimum staining 6 11
moderate staining 18 0
maximum staining 6 0
Bax
no staining 11 23 <0.002*
minimum staining 14 7
moderate staining 5 0
maximum staining 0 0
*Fischer’s exact test.
†Minimum staining (1%-3% positive cells), moderate staining (>3%-
50% positive cells), maximum staining (>50%-100% positive cells).
TaBLe 4. Fistula failure in patients with (study group) and with-
out previously punctured native veins (control group)
Study 
group
Control 
group Total
Fistula failure, % within group 8 (26.7) 2 (6.7) 10 (16.7)
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tivity for Bcl-2 (13,19-22). cfDNA released from blood cells by 
ongoing apoptosis was abundantly present in the plasma of 
hemodialysis patients (23). Their plasma mimicked the ca-
pacity of cfDNA to induce IL-6 in human monocytes, indicat-
ing that this process may contribute to the proinflammatory 
environment observed in hemodialysis patients (23).
Filis et al (13) and Ascher et al (20) explained the lack of 
Bcl-2 expression in varicose veins by the lack of specificity 
of the antibody used to cell types in the vein tissue. Filis et 
al (13) also observed a significant difference in caspase-3 
immunopositivity between varicose vein group and con-
trol group, suggesting an active apoptotic state in varicose 
veins. We observed a significant difference in caspase-3 ex-
pression between study and control group, suggesting an 
active apoptotic state in previously punctured veins used 
for hemodialysis access. Our results are comparable with 
the results of previous studies that found no completely 
specific apoptotic marker for apoptotic cells, requiring the 
use of a combination of techniques (13,24-27).
Filis et al (13) found p53 expression only in the tributary and 
distal great saphenous vein (GSV) of the control group con-
sisting of patients with healthy GSV used for by-pass graft-
ing in open heart surgery. Urbanek et al (28) also found in-
creased p53 expression in the distal GSV of young patients. 
There is evidence that surgical trauma and modified he-
modynamics are associated with endothelial and smooth 
muscle cell damage. Langer et al (29) presumed that the 
uremic environment rather than indirect effects exacerbat-
ed neointimal hyperplasia and calcification within the AVF. 
In the literature there is a discrepancy concerning the Bcl-2 
expression in human medial smooth muscle cells (30,31). 
Hayakawa et al (32) reported that Bax protein expression 
increased with the progression of atherosclerosis, but they 
did not observe Bcl-2 expression. They found that the only 
parameter affecting the maturation time of brachio-basilic 
fistula was vein diameter. AV fistulas using basilica veins 
with diameters larger than 3 mm were shown as suitable 
for hemodialysis in the short term (6,15,30).
Our study found fistula failure to be more common in the 
study group. Smith et al (33) studied samples of the bra-
chial vein used to create AVFs in 15 hemodialysis patients, 
showing significantly greater intimal and medial widths in 
patients who had been treated with hemodialysis less than 
FIgure 2. (A) Positive cytoplasmatic immunohistochemical staining of Bax in the media and intima of the punctured vein, ×200. 
White hyphen indicates the intima; one asterisk indicates the media; two asterisks indicate the adventitia; small black hyphens 
indicate positive cytoplasmatic staining. (B) Positive cytoplasmatic immunohistochemical staining of caspase 3 in the media and 
intima of the punctured vein, ×400. White hyphen indicates the intima; one asterisk indicates the media, small black hyphens indi-
cate positive cytoplasmatic staining. (C) Positive nuclear immunohistochemical staining of p53 in the media of the punctured vein, 
×400. Small black hyphens indicate positive nuclear staining. (D) nuclear immunohistochemical positivity of Bcl-2 in the media of 
the control vein, ×400. Positive reaction, visible as dark staining in the nucleus (black arrows). (E) Positive cytoplasmatic immunohis-
tochemical staining of caspase 3 in the media and intima of the control vein, ×400. White hyphen indicates the intima; black hyphen 
indicates positive cytoplasmatic staining; asterisk indicates the media.
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6 months than in those who had been treated for more 
than 6 months. Moreover, the results showed that the pres-
ent recommendations for a minimum diameter (2 mm) for 
a radial artery and a cephalic vein were sufficient for ad-
equate AVF creation at the wrist. To compare previously 
published data with the results of our study we strictly fol-
lowed the mentioned recommendations for AVF creation 
in all included patients.
A limitation of our study was that there is no specific mark-
er that solely detects apoptotic cells so that the applica-
tion of different techniques would improve the quality of 
our results. Also, the analysis was performed on a relatively 
small number of patients.
In conclusion, our study indicates that previously punctured 
native veins used for hemodialysis exhibit increased apop-
totic activity (caspase 3, Bax) compared with non-punc-
tured veins, which suggests an increased risk of AVF failure 
in patients with previously punctured veins. Further analysis 
on a larger number of specimens is recommended.
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